title: A placebo-controlled trial of gabapentin in spinal muscular atrophy.
abstract: OBJECTIVE
  To evaluate the efficacy of gabapentin in increasing muscle strength of patients with spinal muscular atrophy (SMA).
  
  
  BACKGROUND
  Preclinical data in experimental models of motor neuron disease suggest a neuroprotective effect of gabapentin.
  
  
  METHODS
  Gabapentin (1200 mg), or placebo, was administered three times daily in a randomized, double-blind trial for 12 months. The primary outcome measure was the average percent change from baseline, based on the measurement of strength in four muscles (elbow flexion and hand grip bilaterally) for each patient. Drug efficacy was examined by comparing the percent change in strength for patients on drug vs. placebo. Secondary efficacy variables included: forced vital capacity (FVC), SMA functional rating scale (SMAFRS), and mini-Sickness Impact Profile (SIP).
  
  
  RESULTS
  Eighty-four patients, with type II or III SMA, were enrolled at eight sites across the United States. There were no differences in baseline features. There was no difference between the placebo and drug groups in any outcome measure.
  
  
  CONCLUSIONS
  This study demonstrates the feasibility of this trial design and provides data for the design of future clinical trials in SMA.
authors.affiliation: Department of Neurology, California Pacific Medical Center, Forbes Norris MSDA/ALS Center, 2324 Sacramento Street, #150, San Francisco, CA 94115, USA. rmiller@cooper.cpmc.org
authors.forename: R G
authors.initials: RG
authors.lastname: Miller
authors.forename: D H
authors.initials: DH
authors.lastname: Moore
authors.forename: V
authors.initials: V
authors.lastname: Dronsky
authors.forename: W
authors.initials: W
authors.lastname: Bradley
authors.forename: R
authors.initials: R
authors.lastname: Barohn
authors.forename: W
authors.initials: W
authors.lastname: Bryan
authors.forename: T W
authors.initials: TW
authors.lastname: Prior
authors.forename: D F
authors.initials: DF
authors.lastname: Gelinas
authors.forename: S
authors.initials: S
authors.lastname: Iannaccone
authors.forename: J
authors.initials: J
authors.lastname: Kissel
authors.forename: R
authors.initials: R
authors.lastname: Leshner
authors.forename: J
authors.initials: J
authors.lastname: Mendell
authors.forename: M
authors.initials: M
authors.lastname: Mendoza
authors.forename: B
authors.initials: B
authors.lastname: Russman
authors.forename: F
authors.initials: F
authors.lastname: Samaha
authors.forename: S
authors.initials: S
authors.lastname: Smith
mesh_terms: D000085:Acetates / Q000627:therapeutic use*; D000328:Adult; D000588:Amines; D001132:Arm / Q000503:physiopathology; D003509:Cyclohexanecarboxylic Acids; D004311:Double-Blind Method; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use*; D005240:Feasibility Studies; D005260:Female; D000077206:Gabapentin; D018737:Hand Strength; D006801:Humans; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D012720:Severity of Illness Index; D018434:Sickness Impact Profile; D014897:Spinal Muscular Atrophies of Childhood / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome; D014481:United States; D014797:Vital Capacity / Q000187:drug effects; D005680:gamma-Aminobutyric Acid
chemical_list: D000085:Acetates; D000588:Amines; D003509:Cyclohexanecarboxylic Acids; D018691:Excitatory Amino Acid Antagonists; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin